In high-throughput feed-mill lines, Galla Chinensis Powder Veterinary Grade API is incorporated as a dry, high-tannin botanical fraction into homogeneity-critical medicated premix matrices. The API fraction is milled to a particle size distribution with D90 ≤300 µm and pre-blended with a silica-based carrier at 1:4 in a paddle mixer before final blending. Addition ratios for finished premixes are screened in the range of 5.0–12.0% w/w; these are formulation loading values, not species-specific dosing instructions. Production-scale ribbon mixers of 500 kg capacity achieve a coefficient of variation of ≤5.0% after 10 minutes of main blending when API moisture content is controlled below 5.0% loss on drying measured by USP <921>. The premix must comply with EU Regulation 2019/4 on medicated feed, ISO 22000:2018 feed safety management, and sampling procedures described in ISO 6497:2002. Heavy metal load is verified against USP <232>/<233> elemental impurity limits; residual solvent testing follows VICH GL18(R2). On lines where ambient relative humidity exceeds 60%, caking on the mixer walls and cross-batch carryover are observed; therefore the API is pre-conditioned in a dehumidified hopper at ≤35% RH for a minimum of 4 hours before weighing. The terminal product is a free-flowing premix packed in 25 kg heat-sealed polyethylene-lined paper bags, intended for further dilution into complete feed.

Which Granulation Route Preserves Gallotannin Content in Direct-Compressible Veterinary Tablets?

Direct compression of the unmilled API is unsuitable on high-speed rotary presses because its unmodified powder exhibits compressibility index above 30% and poor die filling at press speeds above 30 rpm. Wet granulation is therefore specified for oral tablet manufacture. The API loading is screened at 20–30% w/w of the tablet core. The powder is loaded into a high-shear granulator fitted with a 5 L bowl; dry mixing proceeds at impeller 300 rpm and chopper 800 rpm for 3 minutes. A binder solution of 5% w/v povidone K30 is sprayed at 8 g/min until granule endpoint is reached, and the wet mass is passed through a 1.2 mm screen. Fluid-bed drying uses inlet air at 55°C while product temperature is kept at ≤45°C to reduce gallotannin hydrolysis; dried granules are sized through 0.8 mm mesh and lubricated with 0.5% magnesium stearate for 2 minutes. Compression on a 12-station instrumented rotary press at 15–25 kN produces cores with hardness 80–120 N and friability ≤1.0% under USP <1217> and USP <1216>. Disintegration is tested by USP <701> in 0.1 N HCl with a limit of ≤15 minutes. Residual solvents are verified under VICH GL18(R2); elemental impurities are controlled per ICH Q3D; manufacturing follows 21 CFR Part 211. Alkaline buffer systems above pH 8 accelerate oxidative browning of gallotannins, so neutral-to-acidic granulating conditions are maintained. The terminal product is an uncoated or film-coated oral veterinary tablet.

Aqueous Soluble Granules and Drinking-Water System Compatibility

Fluid-bed granulation is employed to produce free-flowing soluble granules that disperse without forming tannin-protein floc in hard water. The API loading is 25–40% w/w with maltodextrin DE 12 as carrier and anhydrous citric acid at 2–5% w/w to maintain a reconstituted pH of 4.5–6.0; this pH window minimizes oxidative browning and calcium-polyphenol precipitation. Granulation is performed on a top-spray fluid-bed system with inlet air at 65°C, product temperature 40–45°C, spray rate 12–18 g/min, and final granule moisture ≤3.0% by USP <921>. On production lines, hard water above 300 mg/L CaCO₃ causes deposition of polyphenol–calcium complexes on dosing pump filters; therefore 100 µm in-line filters and citric acid carrier are specified. The terminal product is a soluble granule packed in foil-lined 20 kg bags for proportioned oral administration via drinking water. Regulatory compliance includes USP <232>/<233> for elemental impurities, VICH GL18(R2) for residual solvents, and ISO 22000:2018 for feed additive hygiene.

When Residual Moisture Limits Capsule Filling of Gallotannin Powder

Capsule filling is constrained less by particle size than by hygroscopicity-driven loss of flowability when the API blend is exposed to ambient humidity. Addition of the API into hard capsule formulations is screened at 25–50% w/w; the remaining matrix comprises pregelatinized starch, 0.25% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. The API is pre-dried in a vacuum shelf dryer at 50°C for 6 hours to reach ≤3.0% loss on drying by USP <921>. Blending is conducted in a jacketed V-blender at ≤35% RH and 20°C; compressibility index remains 15–25% when measured by USP <1174>. The powder is filled into size 1 hard capsules on a tamping-type capsule machine operating at 18,000 capsules/hour; fill weight of 300 mg with ±5% tolerance is checked by USP <905>. Uniformity of mass, content uniformity of the gallic acid marker, and moisture are release parameters. Compliance with ICH Q3D elemental impurities and VICH GL18(R2) residual solvents is required. At relative humidity above 60%, the blend forms irreversible clumps and cannot be filled without re-drying. The terminal product is a hard capsule for oral administration to companion animals, packaged with desiccant in PVC/PVDC blisters.

Raw Galla Chinensis Powder is not suitable for parenteral administration without removal of high-molecular-weight gallotannins because the protein-binding astringency causes local tissue precipitation and vein irritation. The injectable-grade downstream route therefore begins with a purified low-molecular-weight polyphenol fraction. The formulation addition ratio is 5.0 mg/mL of purified fraction in Water for Injection; published pharmacokinetic and safety data for this specific configuration is limited, so the loading is established through acute irritation screening rather than efficacy extrapolation. Manufacturing involves extraction in purified water at 90°C for 60 minutes, cooling to 30°C, centrifugation at 10,000×g, and tangential-flow ultrafiltration through 10 kDa polyethersulfone membranes to remove protein-reactive tannins. The permeate is adjusted to pH 5.5–6.5 with sterile 0.1 N hydrochloric acid or sodium citrate, then filtered through 0.22 µm PVDF sterilizing-grade membrane and terminally sterilized at 121°C for 15 minutes. Release testing includes sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, and tannin class verification by Ph. Eur. 2.8.20. The terminal product is a sterile solution filled into 10 mL Type I glass vials under Grade A laminar flow. The manufacturing sequence must comply with 21 CFR Part 211 and EU GMP Annex 1 for sterile medicinal products.

Milling Galla Chinensis Powder for Topical and Intraoral Astringent Powders

Impact milling with air classification is used when the API is destined for dry dusting powders and intraoral astringent preparations. The addition ratio in finished dusting powders is 10–30% w/w; the diluent system is typically kaolin 60–80%, zinc oxide 5–10%, and colloidal silicon dioxide 0.5%. The blend is milled to D90 ≤150 µm using a pin mill with classifier speed adjusted to product specification; residual coarse particles above 500 µm are rejected by in-line sieving. Powder flow is measured by USP <1174>, and microbial quality is controlled by USP <2021> and USP <2022> with absence of Salmonella and Escherichia coli in 10 g samples. Elemental impurities are verified by USP <232>/<233>. In production, the dry blend must be protected from relative humidity above 60%, because gallic acid complexes ferric ion and can produce dark blue-black staining in the presence of iron oxide or iron-containing equipment surfaces. The terminal product is a topical or intraoral dusting powder filled into 250 g HDPE shaker bottles with desiccant closures.